These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 8080260

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The use of potassium channel blocking agents in the therapy of demyelinating diseases.
    Felts PA, Smith KJ.
    Ann Neurol; 1994 Sep; 36(3):454. PubMed ID: 7980830
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine.
    Russell JW, Windebank AJ, Harper CM.
    Mayo Clin Proc; 1995 Jun; 70(6):532-9. PubMed ID: 7776711
    [Abstract] [Full Text] [Related]

  • 5. The myasthenic syndrome: anaesthesia in a patient treated with 3.4 diaminopyridine.
    Telford RJ, Hollway TE.
    Br J Anaesth; 1990 Mar; 64(3):363-6. PubMed ID: 1970263
    [Abstract] [Full Text] [Related]

  • 6. Conduction failure in demyelination: is it inevitable?
    Sears TA, Bostock H.
    Adv Neurol; 1981 Mar; 31():357-75. PubMed ID: 7034486
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of 4-aminopyridine in experimental CNS demyelination.
    Kaji R, Sumner AJ.
    Neurology; 1988 Dec; 38(12):1884-7. PubMed ID: 2848207
    [Abstract] [Full Text] [Related]

  • 10. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis.
    Bever CT, Leslie J, Camenga DL, Panitch HS, Johnson KP.
    Ann Neurol; 1990 Apr; 27(4):421-7. PubMed ID: 2353797
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
    Chan KY, Chang RS, Lau VW, Chan ML, Lai T.
    Ann Palliat Med; 2016 Oct; 5(4):311-314. PubMed ID: 27506750
    [Abstract] [Full Text] [Related]

  • 14. [3,4-diaminopyridine in the treatment of myasthenic syndromes. Practical aspects].
    Vílchez JJ, Casanova B, Monte E.
    Med Clin (Barc); 1996 Jan 13; 106(1):37-8. PubMed ID: 8750543
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Physiology of conduction block in multifocal motor neuropathy and other demyelinating neuropathies.
    Kaji R.
    Muscle Nerve; 2003 Mar 13; 27(3):285-96. PubMed ID: 12635114
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pathophysiology of immune-mediated demyelinating neuropathies-part I: neuroscience.
    Franssen H, Straver DC.
    Muscle Nerve; 2013 Dec 13; 48(6):851-64. PubMed ID: 24006203
    [Abstract] [Full Text] [Related]

  • 19. [3,4-Diaminopyridine-evoked norepinephrine release and B-50 (GAP-43) phosphorylation].
    Huang HY, Tang T, Chen XF.
    Zhongguo Yao Li Xue Bao; 1993 Jan 13; 14(1):35-8. PubMed ID: 8503284
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.